N/A N=225 King Vision® and GlideScope® in Difficult Airways
Airway Management
Primary: Overall Successful Tracheal Intubation for All 3 Video Laryngoscopes - GSAVL, KVChVL and KVNChVL — 72; 61; 72 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
Phase 4 N=135 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
Diabetic Retinopathy
Primary: Mean Average Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye From Month 1 to Study Treatment Completion (Month 12) — 67.4; 65.1; 73.5; 73.8…
Phase 2 N=69 Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Actinic Keratosis
Primary: Part 1: Participants Experiencing Dose Limiting Toxicity (DLT) Based on Local Skin Responses (LSRs) — 0; 0; 2; 1 Participants
Phase 2 N=32 Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
PAH
Primary: Number of Participants With Successful Transition From IV/SC Remodulin to Oral Treprostinil (Cohort 1), From Inhaled Prostacyclin to Oral Treprostinil (Cohort 2), or as…
Phase 2 N=346 Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Lupus
Primary: Percentage of Participants Who Achieve a BICLA Response (BICLA Response Rate) at Day 169 — 59.4; 63.2; 57.4; 58.6 Percentage of participants — p=0.9745
Phase 2 N=80 Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis
Osteomyelitis
Primary: Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population — 97.0; 87.5; 0.0; 12.5 percentage of participants
Phase 4 N=300 Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
Influenza · Healthy
Primary: Percentage of Participants With Fever Greater Than or Equal to (>=) 101 Degrees Fahrenheit (F) — 0; 0 Percentage of Participants
Phase 3 N=205 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 — 6.8; 37.3 percentage of participants — p=<0.001
Phase 2 N=36 Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
Basal Cell Carcinomas
Primary: Number of Treatment-emergent Adverse Events (Including Both Serious and Non-Serious) Causally Related to Study Drug — 0; 0; 0; 2 number of events
N/A N=150 Trial Comparing Iron Supplementation Versus Routine Iron Intake in Very Low Birth Weight Infants
Iron Deficiency Anemia
Primary: Hematocrit (Hct) at 36 Wks Post Menstrual Age (PMA) — 29.2; 28.2 % Hematocrit — p=0.59
Phase 2 N=7 Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Psoriasis
Primary: Psoriasis Area Severity Index — 5.5; 5.0 score on a scale
Phase 3 N=251 Low Dose Aspirin for Venous Leg Ulcers
Venous Leg Ulcer
Primary: Time to Complete Healing of Reference Ulcer — 77; 69 days — p=0.246
Phase 2 N=14 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Overall Survival — 8 Participants
N/A N=50 Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer
Non-melanoma Skin Cancer
Primary: Pain on VAS Score — 2.95; 1.25 score on a scale — p=<0.05